Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Have You Heard

Friday, 13 May 2016

From April 2016, GPs and practice nurses requesting a serum creatinine blood test will be alerted to any significant changes in the patient’s kidney function.

Category: Have You Heard
Friday, 13 May 2016

Dr Matt Kearney, the new national clinical director for Cardiovascular Disease Prevention sets out his vision for cardiovascular disease (CVD) prevention in primary care.

Category: Have You Heard
Thursday, 05 May 2016
The latest WHO report on teenage health reveals some encouraging health improvements in UK schoolchildren, but also highlights growing health inequalities between richer and poorer households.
Category: Have You Heard
Topics covered:
Thursday, 05 May 2016
Diabetes UK has launched a new guide on the management of insulin administration in the community. The guide provides the framework for safe and effective diabetes care in a community setting.
Category: Have You Heard
Topics covered:
Thursday, 05 May 2016
The NHS ‘Think Kidneys’ team has developed a series of online resources to help practices respond to changes in the way blood test warning results for acute kidney injury (AKI) are being managed in path labs across England. The changes mean that results will come direct to practices and will require a more immediate response from GPs and practice nurses.
Category: Have You Heard
Topics covered:
Monday, 25 April 2016

The Obesity Health Alliance (OHA) has announced three key actions that it wants the Government to implement in its forthcoming Childhood Obesity Strategy. The announcement comes as concern mounts over delays in publishing the Government’s Childhood Obesity Strategy.

Category: Have You Heard
Topics covered:
Monday, 25 April 2016

Ezetimibe (Ezetrol®), which is used to treat hypercholesterolaemia in combination with a statin, has been granted a new indication by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is now also indicated to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome when added to ongoing statin therapy or started with a statin.

Category: Have You Heard
Wednesday, 23 March 2016

NICEs recent decision not to approve Sanofis’ lipid-lowering drug alirocumab (Praulent) has been challenged in the light of the approval of evolocumab (Repatha, Amgen) for a limited number of NHS patients who are considered to be statin-intolerant. HEART UK has questioned why NICE did not seek the expertise of lipidologists during its latest review of PCSK9 inhibitors.

Category: Have You Heard
Topics covered:

Article search and filter